First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies - Irenaeus - 2019 - International Journal of Cancer - Wiley Online Library
Anti-CD40 agonistic antibody eradicates tumor and induces transient... | Download Scientific Diagram
InVivoMAb anti-mouse CD40 | Bio X Cell
Anti-CD40 agonist antibodies may be the way to go for bladder cancer
Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice - ScienceDirect
Cancers | Free Full-Text | Agonistic CD40 Antibodies in Cancer Treatment
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study - The Lancet Oncology
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation
Cells | Free Full-Text | Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis
![PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cb235318895039cd45eb055391de568e99105c1/2-Table1-1.png "PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar")
PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar
CD40 therapy and surgery: a potential immunologic partnership. - Abstract - Europe PMC
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma | Nature Communications
CD40 Bioassay
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint - ScienceDirect
List of clinically used agonistic CD40 antibodies | Download Scientific Diagram
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Side effects of CD40 agonistic antibodies versus fusion molecules. | Download Scientific Diagram
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy - Parker Institute for Cancer Immunotherapy
IJMS | Free Full-Text | FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients | Arthritis Research & Therapy | Full Text
Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment - Van Audenaerde - 2020 - Clinical & Translational Immunology - Wiley Online Library
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement - ScienceDirect
